Proof-of-Concept study of GTP-011 (Scopolamine) for the treatment of symptoms of motion sickness.
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2018
Price : $35 *
At a glance
- Drugs Scopolamine (Primary)
- Indications Motion sickness
- Focus Proof of concept; Therapeutic Use
- 10 Apr 2018 Status changed from recruiting to active, no longer recruiting, according to a GT Biopharma media release.
- 06 Apr 2018 New trial record
- 29 Mar 2018 According to the GT Biopharma media release, this trial was initiated in late February 2018 and more than 50% patient has been enrolled in the study.